+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 18Years - 74Years
All Genders
ID07489651

Randomized Study of RE104 Injection to Assess Safety and Effectiveness in Adults with Generalized Anxiety Disorder

Led by Reunion Neuroscience Inc · Updated on 2026-09-24

160

Participants Needed

28

Research Sites

8 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the safety and effectiveness of RE104 for Injection in treating adults with Generalized Anxiety Disorder GAD. This Phase 2 study compares the effects of a single or repeated dose of RE104 to a placebo, aiming to reduce anxiety symptoms as measured by the Hamilton Anxiety Rating Scale and other depression and anxiety assessments. Participants must have a diagnosis of GAD and meet specific health criteria to join. Participants will receive either a single subcutaneous injection of 30 mg RE104 or a placebo injection of 0.9% sodium chloride. The study includes two dosing sessions spaced three weeks apart to observe if one or two doses provide symptom relief. Both groups are monitored under a randomized, double-blind design where neither participants nor researchers know who receives the active drug or placebo. Throughout the study, participants will attend visits at various time points including baseline and weeks 1, 2, 4, 8, and 12 for assessments. These include symptom rating scales for anxiety and depression, monitoring for adverse events, and safety evaluations. The primary outcome is the change in anxiety scores at week 4. Follow-up continues for 12 weeks post-dose to evaluate ongoing effects and safety. Total participation lasts several months, ensuring close monitoring and support.

CONDITIONS

Brief Title

RE104 Safety and Efficacy Study in Generalized Anxiety Disorder

Research Team

M

Mark Pollack Chief Medical Officer, M.D.

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here